이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Verastem 과거 수익 실적

과거 기준 확인 0/6

Verastem은 연평균 9.6%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 15.5%의 비율로 수입이 증가했습니다. 매출은 연평균 40.1%의 비율로 감소했습니다.

주요 정보

9.6%

수익 성장률

39.5%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	-40.1%
자기자본 수익률	-228.3%
순이익	n/a
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

Verastem to highlight potential of ovarian cancer therapy on upcoming investor event

May 26

Analysts Are Betting On Verastem, Inc. (NASDAQ:VSTM) With A Big Upgrade This Week

May 25

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Mar 02

What Is The Ownership Structure Like For Verastem, Inc. (NASDAQ:VSTM)?

Feb 02

Verastem Oncology: Targeting The RAS Pathway To Develop New Cancer Medicines

Jan 12

수익 및 비용 분석

Verastem 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:VSTM 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	0	-106	34	67
31 Dec 23	0	-87	31	61
30 Sep 23	0	-77	28	50
30 Jun 23	0	-75	27	47
31 Mar 23	0	-73	26	49
31 Dec 22	3	-74	25	51
30 Sep 22	3	-73	25	51
30 Jun 22	3	-78	24	49
31 Mar 22	4	-73	24	44
31 Dec 21	2	-71	24	39
30 Sep 21	2	-75	26	38
30 Jun 21	81	-39	38	40
31 Mar 21	84	-45	47	39
31 Dec 20	89	-68	59	41
30 Sep 20	92	-87	75	43
30 Jun 20	22	-130	80	45
31 Mar 20	21	-149	93	46
31 Dec 19	17	-149	101	46
30 Sep 19	15	-122	104	42
30 Jun 19	22	-113	107	41
31 Mar 19	28	-89	93	42
31 Dec 18	27	-72	77	44
30 Sep 18	26	-79	58	46
30 Jun 18	10	-81	38	52
31 Mar 18	0	-76	26	49
31 Dec 17	0	-68	21	46
30 Sep 17	0	-61	19	42
30 Jun 17	0	-46	18	29
31 Mar 17	0	-41	18	24
31 Dec 16	0	-36	17	20
30 Sep 16	0	-37	17	21
30 Jun 16	0	-44	17	28
31 Mar 16	0	-51	17	34
31 Dec 15	0	-58	18	41
30 Sep 15	0	-60	18	43
30 Jun 15	0	-58	18	40
31 Mar 15	0	-55	18	38
31 Dec 14	0	-53	18	35
30 Sep 14	0	-51	17	34
30 Jun 14	0	-48	17	31
31 Mar 14	0	-45	16	29
31 Dec 13	0	-41	15	26

양질의 수익: VSTM 은(는) 현재 수익성이 없습니다.

이익 마진 증가: VSTM 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: VSTM 은(는) 수익성이 없지만 지난 5년 동안 연간 9.6% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 VSTM 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: VSTM 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: VSTM 현재 수익성이 없기 때문에 마이너스 자본 수익률( -228.29% )을 갖습니다.

Verastem 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.35 loss in 1Q 2020)

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.00 loss in FY 2019)

Recent updates

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Price target decreased by 8.5% to US$4.30

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Verastem: Moving Forward

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem Non-GAAP EPS of -$0.11 in-line

Verastem: Looking Increasingly Attractive

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.40

Less than half of directors are independent

Verastem: Time To Take My Position Out Of Mothball

Price target decreased to US$5.50

Consensus forecasts updated

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

No longer forecast to breakeven

Verastem, Inc. Announces Management Changes

Vectoring In On Verastem

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem: Buying Opportunity Following Unjustified Sell-Off

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

Does Verastem (NASDAQ:VSTM) Have A Healthy Balance Sheet?

Verastem to highlight potential of ovarian cancer therapy on upcoming investor event

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Consensus revenue estimates increase to US$1.23m

Analysts Are Betting On Verastem, Inc. (NASDAQ:VSTM) With A Big Upgrade This Week

Consensus revenue estimates fall to US$1.01m

First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.35 loss in 1Q 2020)

Verastem, Inc. Reports Updated Data from the LGSOC Cohort of the Ongoing, Investigator-Sponsored Phase 1/2 Frame Study Evaluating Vs-6766 in Combination with Defactinib in Patients with Recurrent LGSOC

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.00 loss in FY 2019)

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

What Is The Ownership Structure Like For Verastem, Inc. (NASDAQ:VSTM)?

Verastem Oncology: Targeting The RAS Pathway To Develop New Cancer Medicines